Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VGO-Cs01p
- Development stage
- Phase 1
- Lead developer
- Shanghai Vitalgen BioPharma
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
VGO-Cs01p is an investigational cell therapy product consisting of CD7-targeted chimeric antigen receptor (CAR) natural killer (NK) cells derived from human embryonic stem cells. It is being developed for the treatment of CD7-positive relapsed or refractory acute T-lymphoblastic leukemia (R/R T-ALL), particularly in pediatric patients. The therapy aims to harness the cytotoxic potential of engineered NK cells to selectively target and eliminate malignant T-cells expressing the CD7 antigen. The product is currently under evaluation in early phase clinical trials, with a focus on safety and preliminary efficacy[1][2][3][4][6][8].
- Other names
- NK cell derived from human embryonic stem cells
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on VGO-Cs01p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VGO-Cs01p.